Fermer le menu


Member of Lyonbiopole


Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions

in the field of metabolic diseases, primarily diabetes and obesity.

The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1)

The BioChaperone® technology for the development of new generation insulins and products combining

insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an

immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells

transplantation; 4) AdoGel®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has more than 80 employees.

Adocia is listed on the regulated market of EuronextTM Paris (Euronext: ADOC; ISIN: FR0011184241).


Strategic application domain: Human Medicine

Application market: Metabolic Disorders - Endocrinology, Others

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Others

Created on dec. 22nd, 2005 - 80 employees



115 avenue Lacassagne 69003 LYON



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.